Nine Research Priorities to Accelerate Progress Against GI Cancer
During 2017 our Board of Directors and management created a revised Strategic Plan for the organisation and its activities including the development of new clinical trials and translational research. In December 2018, our Scientific Advisory Committee set our research priorities, defining those key areas that address the areas of greatest need and are at the forefront of research.
These areas of research urgently need greater attention and have the potential to significantly improve the knowledge base for clinical decision-making and will address vital unmet needs in GI cancer care.
The current list reflects AGITG’s Research Strategy – to undertake a strategic, multidisciplinary, program-based, collaborative clinical trials portfolio to improve outcomes for patients with gastro-intestinal cancer. It focuses on proactively building the clinical trial portfolio, maximise recruitment and funding opportunities, foster multidisciplinary national and international collaborations, maintain and support a multidisciplinary membership base and maintain efficient and cost-effective structures and processes for optimal use of resources.
Over time, AGITG’s Research Priorities will evolve with the cancer research landscape and will be periodically updated to reflect advancing science and unmet clinical needs.
Professor Tim Price, Chair of AGITG and the Scientific Advisory Committee, says, “Our research priorities have been developed with the ultimate goal of improving patient outcomes. We are looking to the future to ensure that we continue to conduct innovative and ground-breaking research that improves the treatment options and outcomes for patients with GI cancers.”
The research priorities are as follows:
1 Thinking “outside the box” for appropriate new areas for research, including pharmacogenomics, pre-habilitation, and nutrition.
2 Rare cancer possibilities, collaborative approach and investigation into potential future funding.
3 Developing concepts in the rectal cancer space.
4 Clinical trials in HCC and liver SBRT.
5 Rare cancer international collaborations for tumour streams and rare basket studies.
6 Mapping and summarising trial activity elsewhere, using this to inform future research opportunities.
7 Registry-based trials.
8 Late-stage trials, particularly colorectal.
9 Incorporation of Patient Reported Outcomes (PRO’s) into existing and new studies.
Scroll over the images to the right for more …
Watch Professor Steve Ackland and Dr Lorraine Chantrill discuss the AGITG research priorities: